Shares of Compass Therapeutics CMPX have skyrocketed 108.3% in a month after the company announced updates regarding its ...
After the Phase II failure of its lead asset from Cerevel, AbbVie is resetting expectations and narrowing the clinical ...
The Food and Drug Administration on Thursday approved a new type of nonopioid painkiller from Vertex Pharmaceuticals, NBC ...
The COVID-19 pandemic forced investigators conducting clinical trials to use decentralized elements, such as telehealth, to ...
A novel approach developed by scientists, including Rice University chemist James Tour, could transform treatment for ...
“We are excited to support these groundbreaking projects, advancing research from discovery to clinical impact across neurological, psychiatric, cardiovascular, blood, and cancer-related diseases, as ...
Alexander I. Spira, MD, PhD, FACP, discusses the clinical implications of ctDNA for treatment decisions and monitoring in ...
Inc. stock despite strong Phase 2b data. Click for my updated look at MNMD stock and its market opportunities.
A new study shows that oral fecal microbiota transplantation (FMT) is a feasible and safe addition to preventing graft-versus-host disease in patients undergoing stem cell transplantation for blood ...
A 22-month survival benefit was seen for a subset of ALS patients whose disease did not progress when treated with NP001 in ...
NanoViricides, Inc. (NYSE American:NNVC) (the “Company”) today announced that it has engaged a Clinical Research Organization (CRO) to conduct a Phase II clinical trial advancing its broad-spectrum ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback